PE20071043A1 - FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß - Google Patents

FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß

Info

Publication number
PE20071043A1
PE20071043A1 PE2007000155A PE2007000155A PE20071043A1 PE 20071043 A1 PE20071043 A1 PE 20071043A1 PE 2007000155 A PE2007000155 A PE 2007000155A PE 2007000155 A PE2007000155 A PE 2007000155A PE 20071043 A1 PE20071043 A1 PE 20071043A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
aqueous pharmaceutical
erß
alcoxy
Prior art date
Application number
PE2007000155A
Other languages
English (en)
Inventor
Marc S Tesconi
Sherry Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20071043A1 publication Critical patent/PE20071043A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ACUOSA QUE COMPRENDE: A) UN LIGANDO SELECTIVO DEL RECEPTOR ESTROGENICO ER DE FORMULA (I) DONDE R1 ES H, OH, HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R2 Y R2a SON CADA UNO H, OH, ALQUILO(C1-C6), ALCOXI(C1-C4), ALQUENILO(C2-C7), ENTRE OTROS; R3, R3a Y R4 SON CADA UNO H, ALQUILO(C1-C6), ALQUENILO(C2-C7), HALOGENO, ALCOXI(C1-C4), ENTRE OTROS; X ES O, S O NR7, DONDE R7 ES H, ALQUILO(C1-C6), ARILO(C6-C10), ENTRE OTROS; O DE FORMULA (III) DONDE R11, R12, R13 O R14 SON CADA UNO H, OH, ALQUILO(C1-C6), ALCOXI(C1-C6) O HALOGENO; R15, R16, R17, R18, R19 Y R20 SON CADA UNO H, ALQUILO(C1-C6), ALQUENILO(C2-C7), HALOGENO, CN, ENTRE OTROS; SIENDO COMPUESTOS PREFERIDOS: 2-(3-FLUOR-4-HIDROXIFENIL)-7-VINIL-1,3-BENZOXAZOL-5-OL Y 3-(3-FLUOR-4-HIDROXI-FENIL)-7-HIDROXI-NAFTALEN-1-CARBONITRILO; B) UN SOLUBILIZANTE COMPLEJANTE TAL COMO HIDROXIPROPIL BETA-CICLODEXTRINA Y SULFOBUTIL ETER BETA-CICLODEXTRINA QUE SE ENCUENTRAN EN UNA CANTIDAD DE 0,00021% A 60% P/V DE LA COMPOSICION; C) UN COMPUESTO PARA AJUSTAR EL pH TAL COMO NaOH O KOH. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ARTRITIS, ENDOMETRIOSIS
PE2007000155A 2006-02-14 2007-02-13 FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß PE20071043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77302806P 2006-02-14 2006-02-14

Publications (1)

Publication Number Publication Date
PE20071043A1 true PE20071043A1 (es) 2007-10-23

Family

ID=38225453

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000155A PE20071043A1 (es) 2006-02-14 2007-02-13 FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß

Country Status (10)

Country Link
US (1) US20070191442A1 (es)
EP (1) EP1984028A2 (es)
JP (1) JP2009526851A (es)
AR (1) AR059574A1 (es)
AU (1) AU2007215131A1 (es)
BR (1) BRPI0707655A2 (es)
CA (1) CA2641116A1 (es)
PE (1) PE20071043A1 (es)
TW (1) TW200800177A (es)
WO (1) WO2007095286A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080116A1 (es) * 2006-03-06 2008-02-25 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
WO2007103873A2 (en) * 2006-03-06 2007-09-13 Wyeth Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AR059741A1 (es) * 2006-03-06 2008-04-23 Wyeth Corp Formulaciones farmaceuticas liquidas y semisolidas y procedimientos
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
CA2676553A1 (en) * 2007-01-31 2008-08-07 Wyeth Use of er.beta. selective ligands for treating acute lung injuries
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US20040024044A1 (en) * 2000-09-08 2004-02-05 Di Salle Enrico Exemestane as chemopreventing agent
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US6903238B2 (en) * 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
TW200500065A (en) * 2003-05-21 2005-01-01 Wyeth Corp Antiarthritic combinations
EP1761513A1 (en) * 2004-07-01 2007-03-14 Wyeth Tetracyclic compounds as estrogen ligands
BRPI0514974A (pt) * 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
CA2588454A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
AU2005311823A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
AU2005316561A1 (en) * 2004-12-17 2006-06-22 Wyeth The uses of estrogen beta agonists to treat cognitive diseases
AR053332A1 (es) * 2005-02-16 2007-05-02 Wyeth Corp Uso de agonistas selectivos para el receptor-beta de estrogeno (erp) para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion

Also Published As

Publication number Publication date
JP2009526851A (ja) 2009-07-23
BRPI0707655A2 (pt) 2011-05-10
EP1984028A2 (en) 2008-10-29
AR059574A1 (es) 2008-04-16
WO2007095286A2 (en) 2007-08-23
WO2007095286A3 (en) 2007-12-13
US20070191442A1 (en) 2007-08-16
TW200800177A (en) 2008-01-01
AU2007215131A1 (en) 2007-08-23
CA2641116A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
PE20071043A1 (es) FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
BRPI0610343B8 (pt) composto derivado de morfinan substituído por 7-carbamoíla 6,7-insaturada, composição farmacêutica e uso do mesmo
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
TNSN08311A1 (en) Indole sulfonamide modulators of progesterone receptors
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
MY150990A (en) Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
PE20080277A1 (es) Derivados de azaindol espirociclicos y sustituidos
PE20081116A1 (es) Derivados de diaril, dipiridinil y arilpiridinil como antagonistas del receptor opioide
PE20141169A1 (es) Derivados de etinilo
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PE20091182A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-CARBOXAMIDAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20071019A1 (es) Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
UA101162C2 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и применение в терапии
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
PE20061092A1 (es) COMPUESTOS HETEROCICLICOS COMO AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO
PE20110402A1 (es) Derivados de estratieno que comprende biososteros heterociclicos para el anillo fenolico a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal